

**Bijuva (estradiol and progesterone)**  
**Effective 09/01/2025**

<b>Plan</b>	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Medical Benefit</b> <b>Pharmacy Benefit</b>	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
<b>Exceptions</b>	N/A		

**Overview**

Bijuva (estradiol and progesterone) is indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause.

**Coverage Guidelines**

Authorization may be granted for members new to the plan within the past 90 days who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

**OR**

Authorization may be granted when all of the following criteria are met:

1. Member is 18 years of age or older
2. Member has diagnosis of moderate to severe vasomotor symptoms due to menopause
3. Member has had an inadequate response, intolerance or a contraindication to an estrogen and progesterone formulation taken concurrently as separate agents

**Limitations**

1. Approvals will be granted for 12 months

**References**

1. Bijuva (estradiol and progesterone) [prescribing information]. Boca Raton, FL: Therapeutics MD, Inc; November 2023.
2. Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) position statement on menopause-2017 update. *Endocr Pract.* 2017;23(7):869-880. doi: 10.4158/EP171828.PS
3. Simon JA, Kaunitz AM, Kroll R, Graham S, Bernick B, Mirkin S. Oral 17 $\beta$ -estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms. *Menopause.* 2018. doi: 10.1097/GME.0000000000001271
4. ACOG Practice Bulletin No. 141: management of menopausal symptoms. *Obstet Gynecol* 2014; 123:202. Reaffirmed 2018
5. Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. *Cochrane Database Syst Rev* 2017; 1:CD004143

**Review History**

09/18/2019 – Reviewed

09/16/2020 – Reviewed at P&T

09/21/2022 – Reviewed for Sept P&T; Separated Comm/Exch vs MH policies; no clinical updates. Effective

01/01/2023

08/13/2025 – Reviewed and updated for August P&T. Updated language for members who are new to the plan. No clinical changes. Effective 09/01/2025.

